Transient transcription factor (OSKM) expression is key towards clinical translation of in vivo cell reprogramming. Issue 6 (28th April 2017)

• Record Type: Journal Article
• Authors: de Lázaro, Irene; Cossu, Giulio; Kostarelos, Kostas
• Is Part Of: EMBO molecular medicine. Volume 9:Issue 6(2017)
• Page Start: 733
• Page End: 736
• Publication Date: 2017-04-28
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201707650
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract : Reprogramming adult, fully differentiated cells to pluripotency in vivo via Oct3/4, Sox2, Klf4 and c‐Myc (OSKM) overexpression has proved feasible in various independent studies and could be used to induce tissue regeneration owing to the proliferative capacity and differentiation potential of the reprogrammed cells. However, a number of these reports have described the generation of teratomas caused by sustained reprogramming, which precludes the therapeutic translation of this technology. A recent study by the Izpisúa‐Belmonte laboratory described a cyclic regime for short‐term OSKM expression in vivo that prevents complete reprogramming to the pluripotent state as well as tumorigenesis. We comment here on this and other studies that provide evidence that in vivo OSKM induction can enhance tissue regeneration, while avoiding the feared formation of teratomas. These results could inspire more research to explore the potential of in vivo reprogramming in regenerative medicine. Abstract : de Lázaro, Cossu and Kostarelos comment on the prospects of short‐term in vivo OSKM induction to initiate cell reprogramming and enhance tissue regeneration, while avoiding the threat of generating teratomas.